AbbVie Inc. (ABBV)
| Market Cap | 388.97B |
| Revenue (ttm) | 59.64B |
| Net Income (ttm) | 2.35B |
| Shares Out | 1.77B |
| EPS (ttm) | 1.32 |
| PE Ratio | 166.65 |
| Forward PE | 16.86 |
| Dividend | $6.92 (3.14%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 6,631,069 |
| Open | 223.75 |
| Previous Close | 224.13 |
| Day's Range | 219.00 - 225.12 |
| 52-Week Range | 164.39 - 244.81 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 239.16 (+8.67%) |
| Earnings Date | Feb 4, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $239.16, which is an increase of 8.67% from the latest price.
News
MoneyShow's Best Investment Ideas For 2026: Part 1
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an...
AbbVie: The Dividend Does Not Lie
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its pa...
AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.
Shareholders in both drugmakers appear disappointed that a deal may not happen.
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
AbbVie Near Deal for Revolution Medicines
AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter. Revolution Medicines has a market value of around $16 billion. It couldn't be...
AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens.
What Can Trigger A Breakout In Abbvie Stock?
AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpas...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
NORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P.
AbbVie: Rocky Near-Term, Positive Long-Term
AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical s...
My Most Important Warning To Dividend Investors For 2026
The U.S. government is increasingly funding deficits with short-term debt, making interest expenses highly sensitive to Fed policy. A declining average maturity in the sovereign bond index tightens th...
AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV's valuation remains attractive; a 14.4x FY 2027 multiple is compel...
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc
Market movers: The Investment Committee's top stocks to watch right now.
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall...
AbbVie: Unique Mix Of Growth And Value
AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% a...
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving ...
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of ...
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating
AbbVie (ABBV) remains a "Strong Buy" due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline. ABBV's oncology segment is poised for expansion with trispecific antib...
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).